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Abstract 
Objective: Adverse event reports (AERs) submitted to the US Food and Drug Administra-
tion (FDA) were reviewed to confirm platinum agent-associated adverse events, and to clarify 
the rank-order of these drugs in terms of susceptibility. 
Methods: After a revision of arbitrary drug names and the deletion of duplicated submis-
sions, AERs involving cisplatin (CDDP), carboplatin (CBDCA), or oxaliplatin (L-OHP) were 
analyzed. Authorized pharmacovigilance tools were used for the quantitative detection of 
signals, i.e., drug-associated adverse events, including the proportional reporting ratio, the 
reporting odds ratio, the information component given by a Bayesian confidence propagation 
neural network, and the empirical Bayes geometric mean.  
Results: Based on 1,644,220 AERs from 2004 to 2009, CDDP, CBDCA, and L-OHP all 
proved to cause nausea, vomiting, acute renal failure, neutropenia, thrombocytopenia, and 
peripheral sensory neuropathy. Higher susceptibility to nausea was found for CDDP than 
CBDCA and L-OHP. Acute renal failure was also more predominant for CDDP, and CBDCA 
did not increase the blood level of creatinine. A stronger association with thrombocytopenia 
was suggested for CBDCA. Susceptibility to peripheral sensory neuropathy was greatest for 
L-OHP, but less extensive for CDDP and CBDCA. 
Conclusion: The results obtained herein were consistent with clinical observations, sug-
gesting the usefulness of the FDA’s adverse event reporting system, AERS, and the data mining 
method used herein. 
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Introduction 
The chemotherapeutic treatment of solid tumors 
has progressed extensively since the development of 
the  first  platinum  agent,  cisplatin  (CDDP),  in  the 
1970s [1]. Although the precise mechanisms by which 
Ivyspring  
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CDDP exerts its cytotoxic action  has not been fully 
elucidated,  its  effects  on  solid  tumors  have  encour-
aged CDDP-based clinical protocols, and also the de-
velopment of new platinum agents [1, 2]. Today, the 
leading agents include CDDP, carboplatin (CBDCA), 
and oxaliplatin (L-OHP), which share some structural 
similarities, but differ in therapeutic use and  safety 
profiles. 
Besides  acute  effects  such  as  gastrointestinal 
toxicity and myelosuppression, CDDP exerts its most 
toxic effects on organs, such as the nervous system, 
the  organ  of  Corti,  and  the  kidneys  [2,  3].  The 
dose-limiting  toxicity  (DLT)  is  nephrotoxicity,  and 
osmotic diuresis, a prolongation of infusion time, and 
dose fractionation have been tried [2-4]. For CBDCA, 
the DLT is myelosuppression, and the organ toxicity 
is not as problematic, resulting in the replacement of 
CDDP with CBDCA in CDDP-based protocols [2, 4]. 
L-OHP  is  not  nephrotoxic  like  CBDCA,  and  only 
moderately emetogenic, but peripheral sensory neu-
ropathy is its most important toxic effect [2, 4-6].  
Previously,  adverse  event  reports  (AERs)  sub-
mitted  to  the  US  Food  and  Drug  Administration 
(FDA) were reviewed  to  confirm an association  be-
tween platinum agents and hypersensitivity reactions 
[7]. This database relies on spontaneous reports to the 
FDA by health professionals, consumers, and manu-
facturers, and the system is referred to as the Adverse 
Event Reporting System (AERS). To evaluate the re-
sults  quantitatively,  authorized  pharmacovigilance 
methods were used for signal detection [8-14], where 
a signal means a drug-associated adverse event. Here, 
gastrointestinal  toxicity  (nausea,  vomiting),  ne-
phrotoxicity (acute renal failure, an increase in blood 
creatinine  level),  myelosuppression  (neutropenia, 
thrombocytopenia) and peripheral sensory neuropa-
thy  are  focused  on  as  adverse  events  [1-6].  The 
rank-order of CDDP, CBDCA, and L-OHP was clari-
fied in terms of susceptibility to these adverse events 
using statistical indices given by authorized pharma-
covigilance methods [8-14].  
Methods 
Data sources 
The data for this study were retrieved from the 
public  release  of  the  FDA’s  AERS  database,  which 
covers  the  period  from  the  first  quarter  of  2004 
through the end of 2009. The data structure of AERS is 
in  compliance  with  international  safety  reporting 
guidance, ICH E2B, consisting of 7 data sets; patient 
demographic  and  administrative  information 
(DEMO), drug/biologic information (DRUG), adverse 
events  (REAC),  patient  outcomes  (OUTC),  report 
sources  (RPSR),  drug  therapy  start  and  end  dates 
(THER),  and  indications  for  use/diagnosis  (INDI). 
The  adverse  events  in  REAC  are  coded  using  pre-
ferred terms (PTs) in the Medical Dictionary for Reg-
ulatory Activities (MedDRA) terminology. Here, ver-
sion 13.0 of MedDRA was used. 
Prior  to  analysis,  all  drug  names  were  unified 
into  generic  names  by  a  text-mining  approach,  be-
cause AERS permits the registering of arbitrary drug 
names, including trade names and abbreviations. For 
the  batch  conversion  of  drug  names,  reliable  drug 
databases, e.g., the FDA Orange Book, were utilized 
as a dictionary. Spelling errors were detected by GNU 
Aspell and carefully confirmed by working pharma-
cists. Furthermore, drug names which failed to receive 
generic  names  were  manually  converted  to  proper 
names. Foods, beverages, treatments (e.g. X-ray radi-
ation),  and  unspecified  names  (e.g.,  beta-blockers) 
were omitted for this study. Duplicated reports were 
deleted  according  to  FDA's  recommendation  of 
adopting the most recent CASE number (as described 
in one of the downloaded files, 'Asc_nts.doc' from the 
web-site of the FDA AERS database), resulting in the 
reduction of the number of AERs from 2,231,029 to 
1,644,220.  
Data mining 
In pharmacovigilance analyses, data mining al-
gorithms  have  been  developed  to   identify 
drug-associated  adverse  events  as  signals  that  are 
reported more frequently than expected by estimating 
expected reporting frequencies on the basis of infor-
mation  on  all  drugs  and  all  events  in  the  database 
[12-14]. The proportional reporting ratio (PRR) [8], the 
reporting odds ratio (ROR) [9], the information com-
ponent (IC) [10], and the empirical Bayes geometric 
mean (EBGM) [11] are widely used, and indeed, are 
currently employed by the Medicines and Healthcare 
products  Regulatory  Agency  (MHRA),  UK,  the 
Netherlands  Pharmacovigilance  Centre,  the  World 
Health  Organization  (WHO),  and  the  FDA,  respec-
tively.  
All of these algorithms extract decision rules for 
signal  detection  and/or  calculate  scores  to  measure 
the  associations  between  drugs  and  adverse  events 
from a two-by-two frequency table of counts that in-
volve the presence or absence of a particular drug and 
a  particular  event  occurring  in  case  reports.  These 
algorithms, however, differ from one another in that 
the  PRR  and  ROR  are  frequentist  (non-Bayesian), 
whereas the IC and EBGM are Bayesian. In this sec-
tion, only the scoring thresholds used in the present 
study are given, and the reader is referred to review 
articles for details [12-14]. Int. J. Med. Sci. 2011, 8 
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For  the  PRR,  a  given  drug-adverse  event  pair 
was defined as a signal, if the event count was 3 or 
more, and the PRR was 2 or more with an associated 
chi-square value of 4 or more [8], and for the ROR, if 
the lower limit of the 95% two-sided confidence in-
terval (CI) of ROR exceeded 1 [9]. For the IC, IC025, a 
criterion  indicating  the  lower  limit  of  the  95% 
two-sided CI of the IC, was adopted, and an IC025 
value exceeding 0 was defined as a signal [10]. Lastly, 
for  the  EBGM,  an  EB05  of  2  or  more  was  set  as  a 
threshold for signal detection, where the EB05 is in-
terpreted as the lower one-sided 95% confidence limit 
of the EBGM [11]. In this study, AERs were extracted 
for CDDP, CBDCA, and L-OHP, when the signal was 
detected by either the PRR, ROR, IC or EBGM. 
Results 
In  total,  884  adverse  events  were  detected  as 
signals  for  CDDP,  810  for  CBDCA,  and  732  for 
L-OHP.  The  total  number  was  28,382,  24,835,  and 
21,168,  representing  0.13%,  0.11%,  and  0.10%  of  all 
co-occurrences, respectively.  
Nausea/PT10028813,  vomiting/PT10047700, 
acute  renal  failure/PT10038436,  neutro-
penia/PT10029354,  thrombocytopenia/PT10043554, 
and peripheral sensory neuropathy/PT10034620 were 
detected for CDDP, CBDCA, and L-OHP. An increase 
of blood creatinine level/PT10005483 was detected for 
CDDP and L-OHP. The statistical data are listed in 
Tables  1-4.  Diarrhea/PT10012735,  asthe-
nia/PT10003549,  dehydration/PT10012174,  and  py-
rexia/PT10037660 were also detected for all 3 plati-
num agents (data not shown).  
Higher  susceptibility  to  nausea  was  found  for 
CDDP than CBDCA and L-OHP, but L-OHP caused 
vomiting  equally  to  CDDP  (Table  1).  Acute  renal 
failure was also more predominant for CDDP, and no 
CBDCA-associated increase in blood creatinine level 
was detected (Table 2). The association with neutro-
penia was weaker for L-OHP than the others, and a 
stronger  association  with  thrombocytopenia  was 
suggested for CBDCA (Table 3). Susceptibility to pe-
ripheral sensory neuropathy was greatest for L-OHP, 
but less extensive for CDDP and CBDCA (Table 4). 
Discussion 
The AERS database covers several million case 
reports on adverse events. Pharmacovigilance aims to 
search  for  previously  unknown  patterns  and  auto-
matically  detect  important  signals,  i.e., 
drug-associated  adverse  events,  from  such  a  large 
database. Recently developed data mining tools, i.e., 
the PRR, ROR, IC, and EBGM, have been successful at 
detecting signals that could not be found by individ-
ual case reviews and that warrant further investiga-
tion  together  with  continuous  surveillance.  These 
tools are now used routinely for pharmacovigilance, 
supporting  signal  detection  and  decision-making  at 
companies,  regulatory  agencies,  and  pharmacovigi-
lance centers [8-14]. Comparisons of specificity have 
showed that none of these indices is universally better 
than the others [9, 12, 13], but EBGM has the lowest 
sensitivity in this study (Tables 1-4).   
 
Table 1. Signal detection for cisplatin-, carboplatin-, and oxaliplatin-associated gastrointestinal toxicity  
  N  PRR 
(kai2) 
ROR 
(95% two-sided CI) 
IC 
(95% two-sided CI) 
EBGM 
(95% one-sided CI) 
Nausea           
Cisplatin  1083  1.891 
(443.773) 
1.895 * 
(1.784, 2.006) 
0.901 * 
(0.814, 0.988) 
1.865 
(1.773) 
Carboplatin  778  1.511 
(131.593) 
1.513 * 
(1.409, 1.616) 
0.584 * 
(0.482, 0.687) 
1.497 
(1.411) 
Oxaliplatin  673  1.562 
(133.137) 
1.564 * 
(1.449, 1.679) 
0.631 * 
(0.521, 0.741) 
1.546 
(1.451) 
Vomiting           
Cisplatin  1082  2.777 * 
(1201.214) 
2.787 * 
(2.624, 2.951) 
1.448 * 
(1.361, 1.535) 
2.723 * 
(2.590) 
Carboplatin  695  1.980 
(330.798) 
1.983 * 
(1.840, 2.127) 
0.970 * 
(0.862, 1.078) 
1.955 
(1.836) 
Oxaliplatin  743  2.541 * 
(678.261) 
2.547 * 
(2.368, 2.726) 
1.322 * 
(1.217, 1.427) 
2.493 * 
(2.346) 
N: the number of co-occurrences. 
PRR: the proportional reporting ratio, ROR: the reporting odds ratio, IC: the information component, EBGM: the empirical Bayes geometric 
mean. 
*: signal detected, and a signal means a drug-associated adverse event (see “Methods” for the criteria of detection).  
Nausea and vomiting were coded as PT10028813 and PT10047700, respectively. 
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Table 2. Signal detection for cisplatin-, carboplatin-, and oxaliplatin-associated nephrotoxicity 
  N  PRR 
(kai2) 
ROR 
(95% two-sided CI) 
IC 
(95% two-sided CI) 
EBGM 
(95% one-sided CI) 
Acute renal failure           
Cisplatin  388  1.971 
(183.494) 
1.975 * 
(1.787, 2.163) 
0.968 * 
(0.823, 1.112) 
1.948 
(1.791) 
Carboplatin  208  1.177 
(5.346) 
1.178 * 
(1.027, 1.328) 
0.229 * 
(0.033, 0.426) 
1.169 
(1.042) 
Oxaliplatin  198  1.339 
(16.612) 
1.340 * 
(1.165, 1.515) 
0.413 * 
(0.212, 0.615) 
1.327 
(1.179) 
Increase of blood creatinine 
level 
         
Cisplatin  251  2.043 * 
(132.060) 
2.047 * 
(1.808, 2.286) 
1.018 * 
(0.838, 1.197) 
2.012 
(1.812) 
Carboplatin  not detected 
Oxaliplatin  123  1.334 
(9.920) 
1.335 * 
(1.118, 1.551) 
0.405 * 
(0.149, 0.660) 
1.316 
(1.133) 
N: the number of co-occurrences. 
PRR: the proportional reporting ratio, ROR: the reporting odds ratio, IC: the information component, EBGM: the empirical Bayes geometric 
mean. 
*: signal detected, and a signal means a drug-associated adverse event (see “Methods” for the criteria of detection).  
Acute renal failure and increase of blood creatinine level were coded as PT10038436 (renal failure acute) and PT10005483 (blood creatinine 
increased), respectively. 
Table 3. Signal detection for cisplatin-, carboplatin-, and oxaliplatin-associated myelosuppression 
  N  PRR 
(kai2) 
ROR 
(95% two-sided CI) 
IC 
(95% two-sided CI) 
EBGM 
(95% one-sided CI) 
Neutropenia           
Cisplatin  708  6.757 * 
(3418.410) 
6.835 * 
(6.343, 7.328) 
2.724 * 
(2.616, 2.832) 
6.659 * 
(6.257) 
Carboplatin  590  6.287 * 
(2583.368) 
6.346 * 
(5.848, 6.845) 
2.620 * 
(2.502, 2.738) 
6.200 * 
(5.791) 
Oxaliplatin  389  4.935 * 
(1204.217) 
4.964 * 
(4.491, 5.438) 
2.273 * 
(2.129, 2.418) 
4.864 * 
(4.465) 
Thrombocytopenia           
Cisplatin  442  3.373 * 
(729.638) 
3.389 * 
(3.085, 3.693) 
1.735 * 
(1.599, 1.870) 
3.314 * 
(3.061) 
Carboplatin  451  3.852 * 
(940.462) 
3.872 * 
(3.528, 4.216) 
1.923 * 
(1.789, 2.057) 
3.783 * 
(3.496) 
Oxaliplatin  302  3.074 * 
(417.348) 
3.084 * 
(2.753, 3.415) 
1.599 * 
(1.435, 1.763) 
3.009 * 
(2.734) 
N: the number of co-occurrences. 
PRR: the proportional reporting ratio, ROR: the reporting odds ratio, IC: the information component, EBGM: the empirical Bayes geometric 
mean. 
*: signal detected, and a signal means a drug-associated adverse event (see “Methods” for the criteria of detection).  
Neutropenia and thrombocytopenia were coded as PT10029354 and PT10043554, respectively. 
Table 4. Signal detection for cisplatin-, carboplatin-, and oxaliplatin-associated peripheral sensory neuropathy 
  N  PRR 
(kai2) 
ROR 
(95% two-sided CI) 
IC 
(95% two-sided CI) 
EBGM 
(95% one-sided CI) 
Cisplatin  17  3.449 * 
(27.214) 
3.467 * 
(2.151, 4.782) 
1.561 * 
(0.883, 2.240) 
2.675 
(1.754) 
Carboplatin  16  3.629 * 
(27.936) 
3.646 * 
(2.230, 5.062) 
1.609 * 
(0.910, 2.307) 
2.760 
(1.775) 
Oxaliplatin  34  9.217 * 
(241.016) 
9.332 * 
(6.651, 12.013) 
2.878 * 
(2.393, 3.363) 
9.025 * 
(6.734) 
N: the number of co-occurrences. 
PRR: the proportional reporting ratio, ROR: the reporting odds ratio, IC: the information component, EBGM: the empirical Bayes geometric 
mean. 
*: signal detected, and a signal means a drug-associated adverse event (see “Methods” for the criteria of detection).  
Peripheral sensory neuropathy was coded as PT10034620. Int. J. Med. Sci. 2011, 8 
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The AERS database is considered a valuable tool; 
however,  some  limitations  inherent  to  spontaneous 
reporting have been pointed out [12]. First, the data 
occasionally  contain  misspelling  and  miswords,  alt-
hough the structure of AERS is in compliance with the 
international  safety  reporting  guidance.  Second,  the 
system was started more than 10 years ago, and re-
porting patterns have changed over time. Third, the 
adverse events are coded using hierarchical terms of 
PTs  of  MedDRA,  and  changes  in  terminology  over 
time also might affect the quality of the database. Last, 
there are a number of duplicate entries in the data-
base.  To  overcome  problems  with  data  quality,  we 
manually corrected mistakes in the data entities and 
deleted duplicates according to FDA’s recommended 
method. What’s an urgent need is to verify the use-
fulness  of  system  we  developed  by  comparing  the 
data obtained and clinical observations, and here, the 
platinum agent-associated adverse events were ana-
lyzed.  
CBDCA  is  thought  to  be  only  moderately 
emetogenic like L-OHP, when compared with CDDP 
[2]. This clinical observation was demonstrated quan-
titatively herein; a higher susceptibility to nausea was 
found for CDDP (Table 1). However, it is strange that 
L-OHP caused vomiting equally to CDDP, and they 
might differ in the combination of antiemetic drugs. 
The DLT of CDDP is nephrotoxicity, which is said to 
be  less  common  or  absent  in  patients  receiving 
CBDCA  or  L-OHP  [2].  This  was  also  proved  here 
(Table 2). The DLT of CBDCA is myelosuppression, 
and  a  stronger  association  with  thrombocytopenia 
was  suggested  for  CBDCA  (Table 3).  The  most  im-
portant adverse event of L-OHP is peripheral sensory 
neuropathy [2], and again this was confirmed in the 
present study (Table 4). Collectively, the quantitative 
data  obtained  herein  were  consistent  with  clinical 
observations, suggesting the usefulness of the AERS 
database and data mining method, although further 
extensive examinations should be performed.  
In conclusion, AERs submitted to the FDA were 
reviewed  to  confirm  platinum  agent-associated  ad-
verse  events  and  to  clarify  rank-order  in  terms  of 
susceptibility. Based on 1,644,220 AERs from 2004 to 
2009,  it  was  confirmed  that  CDDP,  CBDCA  and 
L-OHP proved to cause nausea, vomiting, acute renal 
failure,  neutropenia,  thrombocytopenia  and  periph-
eral  sensory  neuropathy.  The  rank-order  was  con-
sistent with clinical observations, suggesting the use-
fulness  of  the  AERS  database  and  the  data  mining 
method used herein. 
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